media – Page 2 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

13.8 billion! Leading domestic imaging equipment manufacturer sees significant revenue growth.

Today, United Imaging Healthcare released its preliminary financial results for 2025. The core indicators in the 2025 financial report are all positive, with revenue, net profit and other key indicators increasing by more than 30% . 01 Core Driver Significant performance growth Specifically, in 2025, United Imaging Healthcare’s total revenue reached RMB 13.821 billion, a year-on-year increase of 34.18%, and its net profit attributable to the parent company was RMB 1.888 billion, a year-on-year increase of 49.60%. In addition, many indicators showed significant growth, among which the net profit excluding non-recurring items was RMB 1.788 billion, a substantial year-on-year increase of 77.01%. Based on its outstanding performance in 2025, United Imaging Healthcare’s stock price soared today, with trading volume and turnover skyrocketing. As of 9:40 a.m. today, the highest stock price reached 133.53 yuan, with a single-day increase of up to 5.64%, and a total market value of 108.5 billion ...
- Source: drugdu
- 35
- February 27, 2026
IL-4R antibody submitted for market approval

On February 25, the marketing application of Akeso Biopharma’s IL-4R antibody mandocimab injection was accepted by the NMPA. In August 2025, Akeso announced that its IL-4R antibody, mandocizumab, had achieved all efficacy endpoints in a Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and planned to apply for market approval. Based on inter-study comparisons (non-head-to-head), the efficacy data of mandocizumab is superior to that of the marketed product Dupixent, and it is being further expanded to adolescents. Sanofi’s IL-4R antibody, Dupixent, is the world’s best-selling autoimmune drug, with sales of $18.5 billion in 2025. Image source: Medical Notes Conclusion In the field of autoimmune diseases, Akeso Biopharma will focus on developing dual-target iterative products. The IL-4R/ST2 bispecific antibody AK139 is actively advancing its clinical development and has now reached the Phase II clinical trial stage. https://news.yaozh.com/archive/47273.html
- Source: drugdu
- 31
- February 27, 2026
The Next Blockbuster Drug

Drugs for IgA nephropathy are on the eve of explosive growth. 01 The Next Blockbuster Drug The scarcity of marketed drugs and vast market space once made IgA nephropathy a highly contested battleground for innovative pharmaceutical companies. As the world’s first approved etiological treatment for IgA nephropathy, budesonide enteric coated capsules (brand name: Nefecon / Tarpeyo / 耐赋康) is regarded as the next blockbuster drug. Southwest Securities predicts that sales of budesonide enteric coated capsules could reach 5 billion yuan by 2030. Budesonide enteric coated capsules have already begun to show clear market leadership potential. In 2024, before being covered by medical insurance, the product achieved sales of 353 million yuan in seven months. With volume growth driven by insurance coverage and expanded indications in 2025, sales of budesonide enteric coated capsules surged to over 500 million yuan in Q1–Q3 2025, representing a year-on-year increase of 3,699.89%. At this rate, ...
- Source: drugdu
- 34
- February 27, 2026
【EXPERT Q&A】How can the compliance assessment of in vitro diagnostics (IVDR) in the European Union be carried out in a standardized and efficient manner?

Drugdu.com expert’s response: I. Preliminary Preparation: Clarify Classification and Regulatory Foundations 1. Product Classification According to Annex VIII of the IVDR Regulation (EU 2017/746), in vitro diagnostic devices are categorized into four risk classes: A, B, C, and D: Class A: Low risk (e.g., general laboratory reagents). Non-sterile Class A devices can be self-declared, while sterile Class A devices require notified body involvement. Class B: Medium-low risk (e.g., pregnancy test kits). Requires notified body review of technical documentation and quality management system (QMS). Class C: Medium-high risk (e.g., tumor marker tests). Requires comprehensive notified body review. Class D: High risk (e.g., HIV or HCV tests). Subject to the strictest review, including performance evaluation and clinical data. 2. Regulations and Standards Core Regulation: IVDR (EU 2017/746) and its accompanying guidelines. Harmonized Standards: ISO 13485 (QMS), ISO 14971 (risk management). Unique Device Identification (UDI): Must be registered in the EUDAMED database and ...
- Source: drugdu
- 42
- February 27, 2026
A New Era Dawns

The anticoagulation field has given rise to global blockbuster drugs. For instance, apixaban generated global sales of over $20 billion in 2025. Following the iterations of warfarin and non vitamin K antagonist oral anticoagulants (NOACs), the direction for next generation anticoagulants is now clear: FXI/FXIa inhibitors are set to become an entirely new option in anticoagulation therapy. Recently, Bayer also announced that its FXIa inhibitor asundexian achieved breakthrough positive results in pivotal Phase III clinical trials.The era of FXI/FXIa inhibitors has officially begun. 01Breaking the Deadlock Thrombotic diseases are a group of disorders characterized by the formation of pathological blood clots in arteries or veins. They have become one of the leading global causes of death, directly linked to roughly one quarter of all deaths worldwide each year. According to Frost & Sullivan data, the global number of incident cases of thrombotic diseases reached 26.7 million in 2024, with 7 ...
- Source: drugdu
- 51
- February 26, 2026
Junshi Biosciences and Antengene Corporation Forge Clinical Research Cooperation in Oncology

On February 25, Junshi Biosciences announced a strategic collaboration with Antengene Corporation to jointly explore the synergistic potential of the combination therapy involving Junshi Biosciences’ independently developed JS207 (anti-PD-1/VEGF bispecific antibody) and Antengene’s ATG-037 (oral small-molecule CD73 inhibitor) in cancer patients in Chinese Mainland.JS207 is a recombinant humanized anti-PD-1 and VEGF bispecific antibody independently developed by Junshi Biosciences. It has demonstrated encouraging anti-tumor activity and a manageable safety profile in both preclinical and clinical studies. Preclinical studies have validated its prominent anti-tumor efficacy in multiple tumor models and supported its differentiated mechanism of action. Studies have shown that VEGFA can enhance the antigen-binding activity, T-cell activation potency, and endocytosis of cell-surface PD-1 by JS207. In a poster presentation at the European Society for Medical Oncology Asia (ESMO Asia) 2025, JS207 monotherapy exhibited promising efficacy across multiple solid tumors. Among 62 PD-L1-positive non-small cell lung cancer (NSCLC) patients receiving first-line treatment, ...
- Source: drugdu
- 66
- February 26, 2026
Qilu Pharmaceutical achieves another breakthrough in internationalization, with its blockbuster anti-tumor drug bevacizumab approved for marketing in the UK.

At the beginning of the new year, Qilu Pharmaceutical achieved a new breakthrough in its internationalization strategy. Bevacizumab injection (trade name: Ankevda) received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of various malignant tumors, such as metastatic colorectal cancer, non-small cell lung cancer, breast cancer, kidney cancer, ovarian cancer, and cervical cancer. The UK is a major global pharmaceutical market, and this approval marks the entry of this blockbuster anti-tumor drug into the high-end market. High-quality biopharmaceuticals “Made in China” are gaining widespread recognition worldwide and benefiting more patients. As the world’s first anti-angiogenic monoclonal antibody, bevacizumab is a first-line standard treatment recommended by multiple NCCN guidelines for non-small cell lung cancer and colorectal cancer. Bevacizumab exerts its anti-tumor effects primarily through three mechanisms: inhibiting the degradation of existing vascular systems, suppressing angiogenesis, and reducing vascular permeability. Due to its unique mechanism ...
- Source: drugdu
- 48
- February 26, 2026
Etoposide Injection and Fluorouracil Injection Receive FDA Approval in the United States

Huiyu Pharmaceutical announced on February 25th that it recently received notification from the U.S. Food and Drug Administration (FDA) that its New Drug Applications (NDAs) for etoposide injection and fluorouracil injection have been approved. This means the company can now manufacture and sell these products in the U.S. market through its overseas partners. Etoposide injection is a topoisomerase inhibitor, used in conjunction with other chemotherapy and/or immunotherapy treatments. When used in combination, this treatment is indicated for the following adult patients: 1. Refractory testicular cancer; 2. Small cell lung cancer. Fluorouracil injection is indicated for the treatment of: 1. Colon and rectal cancer; 2. Breast cancer; 3. Gastric adenocarcinoma; 4. Pancreatic cancer. https://finance.eastmoney.com/a/202602253654068331.html
- Source: drugdu
- 44
- February 26, 2026
Jikeqin’s marketing application accepted by the drug regulatory authority

On February 25, Jiuyuan Gene (02566) issued an announcement stating that the marketing application of its developed product, Jikeqin®, has been accepted by the National Medical Products Administration of the People’s Republic of China. This product is a biosimilar of the long-acting glucagon-like peptide receptor agonist smegglutide, designed for weight management in obese or overweight individuals. Glucose control and weight management are achieved by mimicking the physiological effects of endogenous GLP-1 hormones, which promote insulin secretion, inhibit glucagon release, suppress appetite, and delay gastric emptying. In the ongoing Phase III clinical trials, the clinical equivalence study of clopidogrel in obese subjects showed that its primary efficacy endpoint (the rate of change in weight from baseline after 44 weeks of treatment) and safety were clinically equivalent to the reference drug, demonstrating good efficacy and tolerability. https://finance.eastmoney.com/a/202602263654818764.html
- Source: drugdu
- 47
- February 26, 2026
Net profit surged by 1041%, marking a breakthrough for the self-exempt king

Today (February 25), 3SBio released its 2025 preliminary financial results: it expects to achieve revenue of RMB 4.199 billion, a year-on-year increase of 251.81%; net profit attributable to the parent company of RMB 2.939 billion, a year-on-year increase of 317.09%; and net profit attributable to the parent company excluding non-recurring items of RMB 2.805 billion, a year-on-year increase of 1041.01% . However, the story behind the numbers is far more fascinating than the numbers themselves . From the growing pains of strategic transformation in 2022 to the explosive turnaround in performance in 2025, 3SBio has forged a highly representative growth path for innovative Chinese enterprises. 01 Behind the surge in net profit In its preliminary earnings report, 3SBio disclosed that the significant increase in its revenue and net profit in 2025 was due to the important cooperation reached between the company and Pfizer during the reporting period . The company ...
- Source: drugdu
- 49
- February 26, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.